X 910279

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 584721

CAS#: 185915-32-6

Description: X 910279 is a leflunomide analog and a malononitrilamide.


Price and Availability

Size
Price

Size
Price

Size
Price

X 910279 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 584721
Name: X 910279
CAS#: 185915-32-6
Chemical Formula: C14H11N3O2
Exact Mass: 253.0851
Molecular Weight: 253.261
Elemental Analysis: C, 66.40; H, 4.38; N, 16.59; O, 12.63


Synonym: X 910279; HMR 1279; HMR 279; MNA 279; MNA-279; X91 0279

IUPAC/Chemical Name: Cyclopropanepropanamide, alpha-cyano-N-(4-cyanophenyl)-beta-oxo-

InChi Key: GSSLQBZZKKOMAF-UHFFFAOYSA-N

InChi Code: InChI=1S/C14H11N3O2/c15-7-9-1-5-11(6-2-9)17-14(19)12(8-16)13(18)10-3-4-10/h1-2,5-6,10,12H,3-4H2,(H,17,19)

SMILES Code: O=C(NC1=CC=C(C#N)C=C1)C(C#N)C(C2CC2)=O


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>3 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
2934.99.03.00


References

1: Schorlemmer HU, Bartlett RR, Schleyerbach R. Immunomodulatory activity of malononitrilamides, derivatives of leflunomide's primary metabolite, on models of experimental rheumatoid arthritis. Transplant Proc. 1998 Dec;30(8):4137-9. PubMed PMID: 9865326.

2: Schorlemmer HU, Kurrle R, Schleyerbach R, Bartlett RR. Disease-modifying activity of malononitrilamides, derivatives of leflunomide's active metabolite, on models of rheumatoid arthritis. Inflamm Res. 1999 Dec;48 Suppl 2:S113-4. PubMed PMID: 10667840.

3: Schorlemmer HU, Bartlett RR, Lindner JK, Kurrle R. Coadministration of malononitrilamides and tacrolimus induces tolerance in a rat skin allograft model. Transplant Proc. 1999 Feb-Mar;31(1-2):1184-8. PubMed PMID: 10083529.

4: Slauson SD, Silva HT, Sherwood SW, Morris RE. Flow cytometric analysis of the molecular mechanisms of immunosuppressive action of the active metabolite of leflunomide and its malononitrilamide analogues in a novel whole blood assay. Immunol Lett. 1999 Apr 15;67(3):179-83. PubMed PMID: 10369124.

5: Schorlemmer HU, Kurrle R. Combination therapy of malononitrilamides and tacrolimus (FK 506) induced long-term xenograft survival. Transplant Proc. 1998 Dec;30(8):4170-3. PubMed PMID: 9865337.

6: Schorlemmer HU, Kurrle R, Schleyerbach R, Bartlett RR. Generation of O2- radicals in macrophages can be inhibited in vitro and in vivo by derivatives of leflunomide's primary metabolite. Inflamm Res. 1999 Dec;48 Suppl 2:S117-8. PubMed PMID: 10667842.

7: Schorlemmer HU, Bartlett RR, Lindner JK, Kurrle R. Long-term allograft survival and tolerance induction by the synergistic activity of malononitrilamides and tacrolimus. Transplant Proc. 1998 Dec;30(8):4099-103. PubMed PMID: 9865312.

8: Schorlemmer HU, Bartlett RR. Modulation of immunoglobulin dysregulation in graft versus host-and systemic lupus erythematosus-like diseases by malononitrilamides. Transplant Proc. 1998 Dec;30(8):4153-5. PubMed PMID: 9865331.

9: Schorlemmer HU, Bartlett RR, Kurrle R. Malononitrilamides prevent the generation of oxygen radicals in mononuclear phagocytes and graft rejection in a rat model. Transplant Proc. 1999 Feb-Mar;31(1-2):851-3. PubMed PMID: 10083371.

10: Czech J, Kurrle R, Schorlemmer HU. The antiproliferative effect of malononitrilamides (MNAs) on vascular smooth muscle cells is antagonized by exogenous uridine. Inflamm Res. 1999 Dec;48 Suppl 2:S128-9. PubMed PMID: 10667848.

11: Slauson S, Billingham ME, Silva HT, Wang Y, Morris RE. Quilty effect in heterotopic cardiac allografts in malononitrilamide-treated rats. J Heart Lung Transplant. 1999 Dec;18(12):1251-3. PubMed PMID: 10612388.